Source-grounded facts extracted from Sionna Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sionna Therapeutics, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.
“2. To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Sionna Therapeutics, Inc. shareholders approved Election of four Class II directors at the 2026-06-17 meeting.
“1. To elect four nominees as Class II directors: H. Edward Fleming, Jr., M.D., Marcella Kuhlman Ruddy, M.D., Peter A. Thompson, M.D., and Joanne Louise Viney, Ph.D., each to hold office until the Company's Annual Meeting of Stockholders in 2029.”
Sionna Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $26.8 million.
“Sionna Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the three months ended March 31, 2026.”
Sionna Therapeutics, Inc.: Amended and restated bylaws became effective, establishing procedures for stockholder actions at meetings, advance notice procedure for proposals and director nominations, and conforming to amended charter provisions.
“the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”)”
Sionna Therapeutics, Inc.: Fifth amended and restated certificate of incorporation filed, increasing authorized common stock to 500M shares, eliminating references to prior preferred stock series, authorizing 10M undesignated preferred shares, and eliminating stockholder ability to act by written consent and call special meet (effective 2025-01-31).
“the Company filed its fifth amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware on January 31, 2025”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.